AIVITA Biomedical
18301 Von Karman Avenue
Suite 130
Irvine
California
92612
United States
Tel: 949-872-2555
Website: http://aivitabiomedical.com/
About AIVITA Biomedical
AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its products and therapeutic pipeline.
YEAR FOUNDED:
2016
LEADERSHIP:
CEO: Dr. Hans S. Keirstead Ph.D.
CMO: Robert O. Dillman, M.D.
CSO: Gabriel Nistor, M.D.
TECHNOLOGY:
Please click here for AIVITA's technology.
PRODUCTS:
Please click here for AIVITA's products.
99 articles about AIVITA Biomedical
-
AIVITA Biomedical Appoints Dr. H. Christian Fibiger to its Board of Directors
4/5/2022
AIVITA Biomedical, Inc. today announced the appointment of distinguished neuroscientist and industry specialist H. Christian Fibiger, Ph.D. to its board of directors.
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Festival of Biologics
3/9/2022
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that chairman and CEO Dr. Hans S. Keirstead will deliver an opening keynote at the World Immunotherapy Congress, a submeeting of the Festival of Biologics taking place March 9-11 in San Diego.
-
Vaccine development is experiencing a resurgence in the wake of the COVID-19 pandemic, with companies developing a variety of approaches.
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote At Vaccine World Asia Congress
11/16/2021
AIVITA Biomedical, Inc. today announced that chairman and CEO Dr. Hans S. Keirstead will deliver a keynote at the Vaccine World Asia Congress. The Singapore -based congress is being held virtually November 17-18 .
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Deliver Talk at World Immunotherapy Congress Europe
11/8/2021
AIVITA Biomedical, Inc. today announced that chairman and CEO Dr. Hans S. Keirstead will chair a keynote panel and speak on consecutive days at the World Immunotherapy Congress Europe.
-
AIVITA Biomedical's Stem Cell-Derived Retina Transplant Restores Vision Loss in Preclinical Study
10/29/2021
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the publication of the peer-reviewed manuscript, "Co-grafts of Human Stem Cell Derived Retina Organoids and Retinal Pigment Epithelium for Retinal Reconstruction in Immunodeficient Retinal Degenerate Royal College of Surgeons Rats," in the journal Frontiers in Neuroscience.
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Give Keynote Address at Advanced Therapies Congress in London
10/4/2021
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that chairman and CEO Dr. Hans S. Keirstead will deliver a keynote address at the Advanced Therapies Congress & Expo in London, taking place October 5-6.
-
AIVITA Biomedical Announces 96% Immune Response Against SARS-CoV-2 in Phase 2 Clinical Trial of a Personalized Vaccine
9/13/2021
AIVITA Biomedical, Inc. today announced results from its Phase 2 clinical study testing AIVITA's anti-SARS-CoV-2 Vaccine Enabling Kit, which allows ny minimally-equipped facility to make personalized COVID-19 vaccines during the course of 2 patient visits one week apart.
-
The Phase II study showed enhanced immune memory response to the virus in 96% of vaccinated subjects, all of whom were exposed to an environment dominated by the delta variant.
-
AIVITA Biomedical and University of California at Irvine Collaborators Validate 3D Printed Bioreactor for Retinal Organoid Creation
7/13/2021
AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell applications, today announced the publication of the peer-reviewed manuscript, "Retinal organoids on-a-chip: a 3D printed micro-millifluidic bioreactor for long-term retinal organoid maintenance,"
-
AIVITA Biomedical CEO Hans Keirstead Receives 2021 Global Humanitarian Award
3/4/2021
AIVITA Biomedical, a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, today announced that Hans Keirstead , Ph.D., chairman and chief executive officer, will receive Mission Plasticos' 2021 Global Humanitarian Award
-
AIVITA Biomedical Completes Phase 1 Study of Personalized COVID-19 Vaccine Candidate, AV-COVID-19
2/25/2021
AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, today announced the completion of a Phase 1 clinical study in Indonesia of its personalized vaccine candidate, AV-COVID-19, for the novel coronavirus (SARS-CoV-2).
-
AIVITA Biomedical Closes $25 Million Financing Round
12/29/2020
AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, has closed its Series B-2 financing round for up to $25 million . Financing was provided by several life sciences investment firms. Proceeds will support clinical development of AIVI
-
AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
11/17/2020
AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell applications, today announced data from its multi-center Phase 2 clinical trial of its personalized cancer vaccine, AV-GBM-1, in p
-
AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy
11/2/2020
AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell applications, announced today that treatment has been completed for all 57 patients in the Phase 2 clinical trial of AV-GBM-1 in patients with glioblastoma.
-
AIVITA Biomedical's Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Science
10/9/2020
AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and COVID-19, announced today the publication of the peer-reviewed manuscript, "Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction,"
-
AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management
8/3/2020
AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, announced today the publication of the paper, " An update on GM-CSF and its potential role in melanoma management ," in the journal Melanoma Management. Robert O. Dillman , M.D., chief med
-
AIVITA Biomedical CEO Hans Keirstead Named to “20 in 2020” by Consulate General of Canada for Contributions to COVID-19 Research
7/2/2020
AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, announced that Hans Keirstead, Ph.D., chairman and chief executive officer, has been named to the “20 in 2020” by the Consulate General of Canada
-
In the midst of a pandemic, oncology-focused companies virtually unveil data at the American Association for Cancer Research (AACR) Annual Meeting.
-
AIVITA Biomedical Presents Updates from Ongoing Ovarian Cancer and Glioblastoma Clinical Studies at 2020 AACR Virtual Annual Meeting
4/27/2020
AIVITA Biomedical, Inc., a biotechnology company specializing in innovative cell therapy applications, announced today that updates from ongoing clinical trials in ovarian cancer and glioblastoma were presented as part of the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I. The presentation from Daniela Bota, MD, Ph.D., of the University of California, Irvine, and principal investigator